AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04707742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Distilled Water
Description: 15 ml distilled water, one minute rinse.
Study NCT03540784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WB-EMS
Description: WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
Study NCT03540784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional support
Description: dietary monitoring by dietary records; nutritional counselling by dietician, dietary advices: 1.5 g/kg bodyweight/day
Study NCT01498198 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rotator Cuff Repair Surgery
Description: Participants will have surgery within 3 months. They will be followed up at 6 weeks, 12 weeks, 6 months and 12 months pos operatively.
Study NCT01498198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non Operative Treatment
Description: Participants will undergo a 6 week assessment, and if they are improving they will continue undergoing non operative care up until 12 months. If at any assessment point (6 weeks, 12 weeks, 6 months, 12 months) they are deemed to not be making any more progression, they will be referred back to the surgeon.
Study NCT00543426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fuzheng Huayu Tablets
Description: Tablet,three times a day,four tablets one time
Study NCT00543426 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: sham Fuzheng Huayu Tablets (placebo)
Description: Tablet, three times a day, four tablets one time
Study NCT02830776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost 0.03% ophthalmic solution
Description: Latisse (bimatoprost 0.03% ophthalmic solution) applied to the eyelid margin for dermatochalasis (upper eyelid drooping)
Study NCT00906087 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cosopt (combination eyedrop of dorzolamide and timolol)
Description: One drop in each eye every twelve hours for six weeks
Study NCT01086891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen conserving devices
Description: Three 6MWT test will be performed at random with conventional oxygen continuous-flow,by Oxymizer Pendant and demand valve system. The percentage of patients correcting their desaturation and patients' acceptance of every method will be determinated.
Study NCT01086891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen conserving devices
Description: Three 6MWT test will be performed at random with conventional oxygen continuous-flow,by Oxymizer Pendant and demand valve system. The percentage of patients correcting their desaturation and patients' acceptance of every method will be determinated
Study NCT01662674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemigliptin and metformin HCl extended release
Description: Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg, for 1 day
Study NCT01662674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemigliptin/metformin HCl extended release
Description: Administration of combination of gemigliptin 50mg/metformin HCl extended release 500mg, for 1day.
Study NCT00440947 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r)
Description: Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV)+ ritoanvir (/r) for 36weeks followed by ABC/3TC + ATV + /r for 48wks followed by optional treatment extension for 60 weeks on the same regimen
Study NCT00440947 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)
Description: Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV) + ritonavir (/r) for 36 weeks followed by ABC/3TC + ATV for 48wks followed by optional treatment extension for 60 weeks on the same regimen
Study NCT00370279 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scleral buckling, primary vitrectomy
Description: Four different surgical techniques were performed(one in each arm); 1- scleral buckling, 2- primary vitrectomy without encircling band, 3- primary vitrectomy with encircling band, 4- triamcinolone assisted vitrectomy
Study NCT01221220 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Packard Pediatric Weight Control Program
Description: Six-month, family-based, group, behavioral weight control program
Study NCT01221220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Packard Pediatric Weight Control Program plus Home-based advising on environmental changes
Description: Six-month, family-based, group, behavioral weight control program plus Home-based Environmental strategies intervention
Study NCT02716987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831
Description: TAK-831 oral suspension.
Study NCT02716987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PGM299
Description: \[18F\]PGM299 injection
Study NCT04059172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg and acetaminphen 650 mg
Description: For morning appliance placement: dose #1 at approximately 9:00 a.m. as appointment starts; dose #2 6 hours later (3:00 p.m- or as soon after school and close to 3 pm as possible.); dose #3 another 6 hours later (9:00 p.m.); dose #4 the following morning upon waking (approximately 24 hours from start and patient will record the time), doses #5 through #7 will be taken every morning upon waking on the second, third, and fourth days, respectively.~For afternoon appliance placement: dose #1 at approximately 2:00 p.m. as appointment starts; dose #2 6 hours later (8:00 p.m.); dose #3 the following morning upon waking (approximately 12 hours later and patient will record the time); dose #4 6 hours later from dose #3 (approximately 24 hours from the initial dose) around 2:00 p.m. (or as soon after school as possible) doses #5 through #7 will be taken every afternoon at 2:00 p.m. on the second, third, and fourth days, respectively.
Study NCT04059172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 200 mg
Description: For morning appliance placement: dose #1 at approximately 9:00 a.m. as appointment starts; dose #2 6 hours later (3:00 p.m- or as soon after school and close to 3 pm as possible.); dose #3 another 6 hours later (9:00 p.m.); dose #4 the following morning upon waking (approximately 24 hours from start and patient will record the time), doses #5 through #7 will be taken every morning upon waking on the second, third, and fourth days, respectively.~For afternoon appliance placement: dose #1 at approximately 2:00 p.m. as appointment starts; dose #2 6 hours later (8:00 p.m.); dose #3 the following morning upon waking (approximately 12 hours later and patient will record the time); dose #4 6 hours later from dose #3 (approximately 24 hours from the initial dose) around 2:00 p.m. (or as soon after school as possible) doses #5 through #7 will be taken every afternoon at 2:00 p.m. on the second, third, and fourth days, respectively.
Study NCT04059172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: For morning appliance placement: dose #1 at approximately 9:00 a.m. as appointment starts; dose #2 6 hours later (3:00 p.m- or as soon after school and close to 3 pm as possible.); dose #3 another 6 hours later (9:00 p.m.); dose #4 the following morning upon waking (approximately 24 hours from start and patient will record the time), doses #5 through #7 will be taken every morning upon waking on the second, third, and fourth days, respectively.~For afternoon appliance placement: dose #1 at approximately 2:00 p.m. as appointment starts; dose #2 6 hours later (8:00 p.m.); dose #3 the following morning upon waking (approximately 12 hours later and patient will record the time); dose #4 6 hours later from dose #3 (approximately 24 hours from the initial dose) around 2:00 p.m. (or as soon after school as possible) doses #5 through #7 will be taken every afternoon at 2:00 p.m. on the second, third, and fourth days, respectively.
Study NCT02681172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuraceq (florbetaben 18F)
Description: Florbetaben 18F is given as an i.v. injection followed by a flush of sodium chloride solution to ensure full delivery of the dose.
Study NCT02681172 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET
Description: A brain PET scan is usually taken 90 minutes after the i.v. injection of florbetaben 18F.
Study NCT04744207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-248
Description: 120 mg, capsule, once daily for 4 weeks
Study NCT04744207 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule, once daily for 4 weeks
Study NCT03580252 — intervention group
Intervention type: OTHER
Intervention: Correlation analyses for the outcomes
Description: No medical intervention would be done. The single arm would receive regular practice of Hammersmith Assessment and MRI / Ultrasound
Study NCT00573989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Study NCT00573989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Study NCT00573989 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study NCT00573989 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Study NCT01765920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergoferon
Description: 5 ml 3 times a day
Study NCT01765920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 ml 3 times a day
Study NCT03569579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Tab. 10mg
Description: Memantine Tab. 10mg\* 2T/day, QD, PO
Study NCT03569579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Tab. 10mg + Donepezil Tab. 10mg
Description: Memantine Tab. 10mg\* 2T/day + Donepezil Tab. 10mg \* 1T/day, QD, PO
Study NCT02797340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draws and urine samples for metformin concentration measurements
Study NCT02797340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT04117243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: patients will be given 400 microgram misoprostol (2 tablets - Cytotec, Pfizer, G.D. Searle LLC) sublingually immediately before starting skin incision (n=115)
Study NCT04117243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: patients will be given 1 gm (10 ml) TXA (Kapron, Amoun, Egypt) diluted in 20 ml of Glucose 5% (administered as intravenous infusion over 5 minutes, at least 15 minutes prior to skin incision) (n=115)
Study NCT04117243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: patients will receive an intravenous bolus of 5 IU oxytocin (Syntocinon, Novartis, Basel, Switzerland) and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following the delivery of the baby (n=115)
Study NCT01834274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasiglifam (TAK-875)
Description: Fasiglifam (TAK-875) tablets
Study NCT01834274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fasiglifam (TAK-875) Placebo
Description: Fasiglifam (TAK-875) placebo-matching tablets
Study NCT01834274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin tablets
Study NCT01834274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin Placebo
Description: Sitagliptin placebo-matching tablets
Study NCT01834274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin tablets
Study NCT01834274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin tablets
Study NCT04103684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 30mg per kg per day for 5 days followed by course of oral prednisolone
Study NCT04103684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 0.6mg per kg perday for 5 days
Study NCT02025907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin, 100 mg
Description: One 100 mg capsule taken orally (by mouth) once daily.
Study NCT02025907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin, 300 mg
Description: One 300 mg capsule taken orally (by mouth) once daily.
Study NCT02025907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo capsule taken orally (by mouth) once daily.
Study NCT00777101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Tablets 240 mg orally once per day until disease progression or unacceptable toxicity
Study NCT00777101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib
Description: Tablets 1250 mg orally once per day until disease progression or unacceptable toxicity.
Study NCT00777101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Tablets 2000 mg/m² given orally in two evenly divided daily doses for first 14 days of each 21 day cycle. Given until disease progression or unacceptable toxicity.
Study NCT02876588 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unrestricted
Description: Users may open up to 4 patient records at a time.
Study NCT02876588 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restricted
Description: Users are restricted to open 1 patient record at a time.
Study NCT04162574 — intervention group
Intervention type: OTHER
Intervention: Recovery Record
Description: Observational data will be obtained through participants entering data on disordered eating episodes, mood, and food in Recovery Record, an app to assist people in managing their eating disorder during the 30 days of the trial. In addition, participants wear an Apple Watch from which passive data (e.g., heart rate, activity, and geolocation) are collected.
Study NCT02651584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAM2038 SC injection
Study NCT02651584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL BPN/NX tabs
Study NCT02651584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo SC injections
Study NCT02651584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL placebo tablets
Study NCT00823355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: forodesine hydrochloride
Description: Cohort 1: 100mg / body (1 x 100mg tablet once daily)
Study NCT00823355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: forodesine hydrochloride
Description: Cohort 2: 200mg / body (2 x 100mg tablets once daily)
Study NCT00823355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: forodesine hydrochloride
Description: Cohort 3: 300mg / body (3 x 100mg tablets once daily)
Study NCT00823355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: forodesine hydrochloride
Description: Cohort 4: 400mg / body (4 x 100mg tablets once daily)
Study NCT01870427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (2.0 mg)
Description: Intravitreal Aflibercept (2.0 mg)
Study NCT01265797 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cranial Electrostimulator
Description: participant wears active cranial electrostimulation device for 20 minutes daily for 28 days
Study NCT01265797 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: participant wears sham device for 20 minutes daily for 28 days
Study NCT02794324 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Voluntary deep-inspiratory breath hold
Description: Patients undergoing scanning in v_DIBH will be positioned supine with arms extended on a MedTec breast board. They will be monitored visually on screen and will be given a buzzer to press when they have taken a breath. CT images will be obtained during DIBH. If the patient needs to release their breath, they will be asked to press the buzzer a second time. Patients will be closely monitored by radiographers via CCTV.
Study NCT02794324 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active-breathing-controlled deep-inspiratory breathhold
Description: Patients undergoing scanning in ABC_DIBH will be positioned supine with arms extended on a MedTec breast board to which an activated-breathing control device (Elekta, Crawley, UK) has been attached. They will breathe through the device. During ABC_DIBH, CT images will be obtained.
Study NCT02794324 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prone treatment
Description: Patients undergoing scanning in a prone position will lie on a customised prone treatment platform. CT images will be acquired under free-breathing conditions.
Study NCT02794324 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active-breathing-controlled deep-inspiratory breathhold
Description: The ABC unit allows for temporary and reproducible immobilization of internal thoracic structures by monitoring the patient's breathing cycle and implementing a breath hold at a predefined lung volume level. The device consists of a mouthpiece connected to a pneumotachometer via a bidirectional valve and tubing. The air flow across the pneumotachometer is integrated and displayed on a computer monitor. The computer also controls a scissor valve which, when enabled, restricts air flow through the system, enabling the breath hold phase. The mouthpiece and air filter are patient specific, as is a nose clip that is used to ensure that patients are breathing through the device.
Study NCT04245475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality psychological pain reduction
Description: attention distraction
Study NCT04245475 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality psychological pain reduction
Description: attention distraction
Study NCT01055600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: Mothers are taking PROMACTA prescribed by their physician before entering this study. No drug will be administered as part of this study.
Study NCT01452763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 10 mg tablets, orally, once daily for up to 24 weeks.
Study NCT01452763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
Study NCT01452763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 20 mg tablets, orally, once daily for up to 24 weeks.
Study NCT01452763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole 15 mg capsules, orally, once daily for up to 24 weeks.
Study NCT01452763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: TAK-438 placebo-matching tablets, orally, once daily for up to 24 weeks.
Study NCT01748279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Study NCT01748279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: 12mcg of Foradil BID as maintenance COPD treatment in both treatment arms
Study NCT01748279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Formoterol
Description: 12mcg of Foradil BID as maintenance COPD treatment in both treatment arms
Study NCT01748279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose tablet
Description: One lactose tablet taken once a day as add-on treatment to Formoterol therapy
Study NCT00964743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DepoCyt
Description: Patients were to receive DepoCyt through a reservoir every 2 weeks for 5 doses, then every 4 weeks for an additional 5 doses.
Study NCT00964743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Patients received oral sorafenib at 400 mg twice a day
Study NCT01784770 — intervention group
Intervention type: DRUG
Intervention: Azithromycin IV
Description: The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with community-acquired pneumonia due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for at least two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as two 250-mg tablets to complete a 7- to 10-day course of therapy.~The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pelvic inflammatory disease due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for one or two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day course of therapy.
Study NCT03068442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imaging with flutemetamol F 18 PET/CT
Description: All subjects will undergo diagnostic imaging as the intervention. This imaging will be with flutemetamol F 18 PET/CT
Study NCT00781911 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Participants will receive cixutumumab IV 10 mg/kg over 1 hour every 2 weeks. Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.